

## Treatable cerebellar ataxias

Chairs : Kinya Ishikawa

The Center for Personalized Medicine for Healthy Aging

Yoshio Ikeda

Department of Neurology, Gunma University Graduate School of Medicine

---

HT-08-1

### Ataxic form of autosomal recessive PEX10-related peroxisomal biogenesis disorders

Toru Yamashita

Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

**HT-08-2** Anti-GAD antibody positive cerebellar ataxia

**Kazunori Nanri**  
Sassa General Hospital

**HT-08-3** Cerebellar ataxic form of Hashimoto's encephalopathy

**Makoto Yoneda**  
Faculty of Nursing & Social Welfare Sciences, Fukui Prefectural University

**HT-08-4** Paraneoplastic cerebellar ataxia

**Keiko Tanaka**  
Department of Animal Model Development, Brain Research Institute, Niigata University /  
Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, School of  
Medicine

**HT-08-5** Metabolic and drug-induced ataxia

**Yoshio Ikeda**  
Department of Neurology, Gunma University Graduate School of Medicine

**HT-09 Hot Topics 09****En**

May 24 (Fri) 13 : 45 ~ 15 : 45 Room 10 (Osaka International Convention Center 12F Grande Toque)

**Critical care in epilepsy**

Chairs : **Akio Ikeda**  
Department of Epilepsy, Movement Disorders and Physiology, Kyoto  
University Graduate School of Medicine, Japan

**Masako Kinoshita**  
Department of Neurology, Utano National Hospital, National Hospital  
Organization, Japan

**HT-09-1** Nonconvulsive seizures and status epilepticus in the critically ill: the silent epidemic

**Lawrence J. Hirsch**  
Professor of Neurology and Chief of Epilepsy/EEG at Yale University, USA

**HT-09-2** Seizures in the emergency department: benefits and limitations of clinical guidelines

**Kazuhiro Kato**  
Japanese Red Cross Ishinomaki Hospital, Japan

**HT-09-3** New Onset Refractory Status Epilepticus (NORSE) : Diagnosis and Treatment

**Yuto Uchida**  
Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Japan  
/Department of Neurology, Toyokawa City Hospital, Japan

**HT-09-4** Sudden unexpected death in epilepsy (SUDEP)

**Kazutaka Jin**  
Department of Epileptology, Tohoku University Graduate School of Medicine, Japan

**HT-09-5** Handling psychogenic nonepileptic seizures emergency cases

**Go Taniguchi**  
Department of Neuropsychiatry, The University of Tokyo Hospital, Japan

**Guideline for Parkinson disease**

Chairs : Nobutaka Hattori

Department of Neurology, Juntendo University

Hirohisa Watanabe

Department of Neurology &amp; Neuroscience, Fujita Health University

**G-02-1 New Clinical Diagnostic Criteria for Parkinson's Disease**

Satoshi Orimo

Department of Neurology, Kanto Central Hospital

**G-02-2 Treatment of early Parkinson Disease**

Atsushi Takeda

Department of Neurology, Sendai-Nishitaga Hospital

**G-02-3 Treatment of Advanced Parkinson's disease**

Yasushi Shimo

Department of Neurology, Juntendo University School of Medicine

**S-20 Symposium 20****Diagnosis and Treatment of Duroopathies**

Chairs : Takemori Yamawaki

Hiroshima City Hiroshima Citizens Hospital

Keita Sakurai

Department of Radiology, Teikyo University School of Medicine

**S-20-1 The concept and imaging findings of duroopathies**

Akira Yagishita

Tokyo Metropolitan Neurological Hospital, Dept. Neuroradiology

**S-20-2 The diagnosis and treatment of CSF leak**

Takashi Mitsufuji

Department of neurology, School of Medicine, Saitama Medical University

**S-20-3 Diagnosis and Treatment of Superficial Siderosis**

Takemori Yamawaki

Hiroshima City Hiroshima Citizens Hospital

**S-20-4 Dose Hirayama disease have a duroopathic nature?**

Toshio Fukutake

Department of Neurology Kameda Medical Center

Nominal support: The Japanese Society of Neuroradiology

**A compass for deciphering the pathophysiology of migraine**

Chairs : Takao Takeshima

Tominaga Hospital, Headache Center, Department of Neurology

Toshihiko Shimizu

EBARA CORPORATION

**S-21-1 The clarification of migraine pathophysiology  
-the compass from in vivo study**

Eiichiro Nagata

Department of Neurology, Tokai University School of Medicine

**S-21-2 Insight into migraine pathophysiology gained from in vitro studies**

Mamoru Shibata

Department of Neurology, Keio University School of Medicine

**S-21-3 Compass for breakthrough of pathophysiology in migraine from  
neurophysiological studies**

Koichi Shibata

Department of Medicine (Neurology), Tokyo Women's Medical University Medical Center East

**S-21-4 Physiopathology of Migraine:  
What have we learned from functional imaging?**

Noboru Imai

Department of Neurology, Japanese Red Cross Shizuoka Hospital

Nominal support: The Japanese headache society

**Crosstalk between brain and liver**

Chairs : Hiroaki Miyajima

First Department of Medicine, Hamamatsu University School of Medicine

Yoshiki Sekijima

Department of Medicine (Neurology &amp; Rheumatology), hinshu University

School of Medicine

**S-22-1 Precise diagnosis of Wilson disease**

Akihiro Matsuura

Fujita Health University School of Medicine

**S-22-2 Pathomechanism and development of effective therapies for adult-onset citrullinemia (CTLN2)**

Masahide Yazaki

Institute for Biomedical Sciences, Shinshu University / Shinshu University School of Health Sciences

---

**S-22-3** Cerebrotendinous xanthomatosis: molecular pathogenesis and disease-modifying treatments

Shingo Koyama

Department of Internal Medicine III, Yamagata University School of Medicine

---

**S-22-4** hereditary ATTR cerebral amyloid antipathy and liver transplantation

Taro Yamashita

Department of Neurology, Graduate School of Medical Sciences, Kumamoto University /  
Organization Project of Practice System for Neurological Intractable Disease, Kumamoto  
University Hospital

---

**S-23 Symposium 23**

Proposed symposium **Jp**

May 24 (Fri) 8:00 ~ 9:30 Room 11 (Osaka International Convention Center 12F Conference Room 1202)

---

**What is the first thing that the neurologist do when there is a disaster?**

Chairs : Kouichi Mizoguchi

Shizuoka Medical Center

Osamu Yamamura

Department of Neurology, University of Fukui Hospital

---

**S-23-1** DMAT activity in the disaster medicine

Yuichi Koido

National Hospital Organization Disaster Medical Center

---

**S-23-2** Activity of Perinatal and Pediatric Disaster Medical Liaison

Miho Misaki

National Disaster Medical Center

---

**S-23-3** Practice of Disaster Medicine:  
Patient image of a neurological disease encountered at a shelter

Osamu Yamamura

Department of Neurology, University of Fukui Hospital

---

**S-23-4** Individual evacuation support plan at disaster for patients with intractable diseases

Chizu Wada

Akita national hospital

---

**S-23-5** Disaster Response of Japanese Society of Neurology

Kouichi Mizoguchi

Shizuoka Medical Center

---

**Potential disease modifying therapies for Parkinson disease**

Chairs : Atsushi Takeda  
National Hospital Organization, Sendai-Nishitaga Hospital, Japan  
Kenya Nishioka  
Juntendo University School of Medicine, Japan

**S-24-1** Therapies for PD via modifying actions of extracellular alpha-synuclein  
Seung-Jae Lee  
Department of Biomedical Sciences, Seoul National University College of Medicine, Korea

**S-24-2** Challenges in trials of disease modifying therapies in Parkinson disease  
Camille Carroll  
University of Plymouth Faculty of Medicine and Dentistry, UK / University Hospitals  
Plymouth NHS Trust, UK

**S-24-3** In silico drug screening by using GWAS-data for Parkinson's disease  
Tatsushi Toda  
Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan

**S-24-4** Cholinesterase inhibitor may improve PD prognosis  
Toru Baba  
Department of Neurology, Sendai-Nishitaga National Hospital, Japan

**New drug development and the change of treatment strategy in MG**

Chairs : Tomihiro Imai  
Sapporo Medical University School of Health Sciences, Japan  
Hiroyuki Murai  
International University of Health and Welfare, Japan

**S-25-1** Overview:  
Why is the development of new treatment necessary in MG area?  
Tomihiro Imai  
Sapporo Medical University School of Health Sciences, Japan

**S-25-2** New Drug Development for Myasthenia Gravis  
Henry J. Kaminski  
George Washington University, USA

**S-25-3** Challenges and developments in MG care in Europe  
Maria I Leite  
University of Oxford, UK / Oxford University Hospitals NHS Foundation Trust, UK

S-25-4 The innovative treatment strategy for patients with myasthenia gravis in Taiwan

Hou-Chang Chiu

Fu-Jen Catholic University Hospital, Taiwan / Shin Kong WHS Memorial Hospital, Taiwan /  
College of Medicine, Fu-Jen Catholic University, Taiwan

S-25-5 A possible new treatment for MG:  
Fc fusion protein, AChR-Fc

Akiyuki Uzawa

Department of Neurology, Graduate School of Medicine, Chiba University, Japan

## S-26 Symposium 26

Jp

May 24 (Fri) 13 : 45 ~ 15 : 45 Room 5 (Osaka International Convention Center 10F Conference Room 1005-1007)

### Pregnancy planning and outcome in neuroimmunological disorders

Chairs : Izumi Kawachi

Dept. of Neurology, Brain Research Institute, Niigata University

Kazuo Fujihara

Fukushima Medical University

S-26-1 Pregnancy in women with multiple sclerosis and neuromyelitis optica  
Yuko Shimizu

Department of Neurology, Tokyo Women's Medical University

S-26-2 Pregnancy and birth on the course of myasthenia gravis  
Shigeaki Suzuki

Keio University School of Medicine, Department of Neurology

S-26-3 Pregnancy of patients with rheumatic diseases accompanying  
neurological symptoms

Atsuko Murashima

National Center for Child Health and Development, Division of Maternal Medicine, Japan Drug  
Information Institute in Pregnancy

S-26-4 A review of infertility treatment; Assisted Reproductive Technology  
for immune neurological diseases

Keiichi Kato

Kato Ladies Clinic

**Current topics in Guillain-Barré syndrome  
- from pathophysiology to clinical features**

Chairs : Kenichi Kaida

Division of Neurology, Department of Internal Medicine, National Defense  
Medical College, Japan

Atsuro Chiba

Departemnt of Neurology, School of Medicine, Kyorin University, Japan

**S-27-1****Recent advances of anti-glycolipid antibody research in GBS**

Hugh Willison

University of Glasgow, Scotland

**S-27-2****Ca<sup>2+</sup>-dependent anti-GQ1b antibody:****From a new assay method to an insight for paranodal gangliosides**

Atsuro Chiba

Department of Neurology, Faculty of Medicine, Kyorin University, Japan

**S-27-3****New observations from the International GBS Outcome Study (IGOS)**

Bart Jacobs

Departments of Neurology and Immunology, Erasmus University Medical Center, The  
Netherlands**S-27-4****Nodopathy:****The third electrophysiologic category in Guillain-Barré syndrome**

Satoshi Kuwabara

Department of Neurology, Graduate School of Medicine, Chiba University, Japan

**S-27-5****Guillain-Barré syndrome in Japan; clinical features and prediction of  
prognosis**adopted from  
free papers

Yuko Yamagishi

Department of Neurology, Kindai University, Faculty of Medicine, Japan

**New concepts of glia and brain homeostasis:  
key missing pieces in the puzzle of neurological disorders**

Chairs : Koji Yamanaka

Research Institute of Environmental Medicine, Nagoya University, Japan

Makoto Higuchi

National Institutes for Quantum and Radiological Science and Technology,  
Japan**S-28-1****Overview: glia as therapeutic targets for neurodegenerative diseases**

Koji Yamanaka

Research Institute of Environmental Medicine, Nagoya University, Japan



S-28-2 Regulatory T cell modulation of neuroinflammation and progression in amyotrophic lateral sclerosis

Bradley Turner

Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia

S-28-3 Reactive Astrocytes, MAO-B, GABA, Hydrogen Peroxide, and Alzheimer's Disease

C. Justin Lee

Institute for Basic Science, Korea

S-28-4 Novel function of lipid mediators for the microglial fate determination of injured neurons

Hiroshi Kiyama

Dept. of Functional anatomy & Neuroscience, Grad. Sch. Med., Nagoya University, Japan

S-28-5 Novel homeostatic function of glial cells in health and disease

Makoto Higuchi

National Institutes for Quantum and Radiological Science and Technology, Japan

## S-29 Symposium 29

Jp

May 24 (Fri) 13 : 45 ~ 15 : 45 Room 9 (Osaka International Convention Center 12F Conference Hall)

### Drug development by open innovation with pharmaceutical company

Chairs : Takanori Yokota

Tokyo Medical and Dental University

Sonoko Misawa

Chiba University Graduate School of Medicine

S-29-1 Industry Academia Alliance

Kaori Iida

Professor Director Institute of Research Division for Research Innovation Research Center for Industry Alliances /Acting Director Institute of Open Innovation Tokyo Medical and Dental University (TMDU)

S-29-2 Expectation to academia with accelerated diversification of pharmaceutical modality

Yasushi Kajii

Neuroscience Medical Franchise Department, Medical Division, Novartis Pharma K.K.

S-29-3 Roles of life sciences startup companies in medical innovation

Koichi Ashida

INCJ, Ltd.

S-29-4 Support of drug development by academic-industrial collaboration

Haruhiko Hakuno

Director, Research and Development Division, Health Policy Bureau, Ministry of Health, Labour and Welfare

S-29-5 Global trend of drug development for CNS diseases

Keiji Yamamoto

Innovative Biology Labs., Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Ltd.

**To the ocean of Brain visualization research**

Chairs : Hirohisa Watanabe

Department of Neurology &amp; Neuroscience, Fujita Health University

Hitoshi Shimada

Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

**S-30-1 Recent advances of 7T ultra high field MRI in neuroimaging research**

Masaki Fukunaga

Division of Cerebral Integration, National Institute for Physiological Sciences / School of Life Science, The Graduate University for Advanced Studies (SOKENDAI)

**S-30-2 A network-based analysis for higher brain function**

Wataru Sako

Department of Clinical Neuroscience, Tokushima University Graduate School

**S-30-3 Next generation PET studies toward developing disease modifying therapies**

Hitoshi Shimada

Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

**S-30-4 EIRL: The medical image diagnostic technology with AI**

Yoshiki Soeda

LPixel Inc.

**S-30-5 Usefulness of diffusion MRI for MRI-negative neurological disorders**

Yukio Kimura

National Center of Neurology and Psychiatry Hospital, Department of Radiology

**Let's start the basic research even after the clinical training by the presidents of scientific societies**

Chairs : Tatsushi Toda

Department of Neurology, Graduate School of Medicine, The University of Tokyo

Hideki Mochizuki

Department of Neurology, Osaka University

**SS-05-1 The attraction of basic research**

Tatsushi Toda

Department of Neurology, Graduate School of Medicine, The University of Tokyo

---

SS-05-2

Welcome to basic sciences, a message from the President of the Japan Neuroscience Society

Tadashi Isa

Graduate School of Medicine, Kyoto University / Institute for the Advanced Study of Human Biology, Kyoto University / Human Brain Science Center, Kyoto University

---

SS-05-3

Wonderful world created by the research in neurochemistry

Keiji Wada

National Institute of Neuroscience, National Center of Neurology and Psychiatry

Nominal support: The Japanese Society for Neurochemistry, The Japan Neuroscience Society